Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Changes in Boards of Revenio Group Corporation's subsidiaries

Revenio Group Corporation, Stock Exchange Release, January 2, 2017 at 15:00



CHANGES IN BOARDS OF REVENIO GROUP CORPORATION'S SUBSIDIARIES

The composition of the Board of Directors will change in Revenio Group
Corporation's subsidiaries Icare Finland Oy, Revenio Research Oy, Done Medical
Oy and Oscare Medical Oy.

As announced on 16 May 2016, Olli-Pekka Salovaara, Revenio Group Corporation's
long-term President & CEO resigned on 31 December 2016. At the same time, he
resigned from board membership in the above-mentioned subsidiaries.

Timo Hildén, who assumed the position of the Group's new President & CEO on 1
January 2017 and has been a deputy member on the boards of Icare Finland Oy,
Revenio Research Oy and Done Medical Oy will become an ordinary member of these
boards, and Robin Pulkkinen, the Group's CFO, will be appointed a deputy member
of the boards. Tomi Karvo, Icare Finland Oy's Sales and Marketing Director, has
been appointed a new member of Oscare Medical Oy's Board of Directors, and Timo
Hildén has been appointed Chairman of the Board of Directors.



Revenio Group Corporation
Timo Hildén
President & CEO


For further information, please contact:

Timo Hildén, President & CEO, tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi


DISTRIBUTION:

NASDAQ Helsinki
Financial Supervisory Authority
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.



[]